Apr 05 2016

Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discovery

Leveraging its instrumental contribution to the BioIntelligence consortium, Ipsen has decided to deploy the 3DEXPERIENCE platform

Paris (France), April 5, 2016 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, and Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced their collaboration for innovative programs using the 3DEXPERIENCE platform.

Ipsen has selected the “Designed to Cure” industry solution experience to accelerate its research and development (R&D) transformation and discovery of new therapeutic solutions. The platform offers data integration, modeling and simulation capabilities to gain a more comprehensive view of the dysregulations linked to diseases as well as improves and shortens the identification of higher quality drug candidates. The project also aims to optimize the R&D processes of Ipsen’s multi-disciplinary teams located in the heart of the leading biotechnological and life sciences hubs in France, the U.K. and the U.S., as well as those of its worldwide network of drug development partners including world-class scientists, Biotechs, clinical research organizations, and other stakeholders.

“After more than five years of partnering with Dassault Systèmes on the BioIntelligence, we are pleased to achieve a key step in our collaboration with the deployment of this set of cutting edge innovative tools,” said Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, Ipsen“Ipsen as a key scientific partner has ‘open innovation’ in its DNA and this new collaborative and innovative digital platform will support Ipsen’s commitment to achieve therapeutic breakthroughs in patient care.”

“The virtual world offers the pharmaceutical industry opportunities to reinvent collaboration, connect unrelated disciplines and simulate human biological complex phenomena like never before,” said Jean Colombel, Vice President, Life Sciences Industry, Dassault Systèmes“Our partnership with Ipsen on the adoption of the 3DEXPERIENCE platform furthers the promise of the 3D experience approach by bridging life sciences disciplines and delivering innovative patient experiences.”